Knoa Pharma was founded to help abate the opioid crisis. That public health purpose drives everything we do.

Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health.

We expand access to lifesaving overdose reversal medicines and deliver affordable treatments for opioid use disorder, while ensuring the safe and responsible distribution of medicines that are critical to patient care, including opioid analgesics. We also innovate to address unmet patient needs and enhance our robust generics portfolio.

Owned by a not-for-profit foundation, every aspect of the business is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference.

We are guided by a public health purpose and operate with transparency and accountability to the public.

We are Knoa Pharma.

Latest Stories

Knoa Pharma to Present Pipeline Assets at LSX Congress USA 2026

The Company will showcase its investigational pipeline assets and invite conversations with potential partners at the Congress, September 23-24, in Boston. 

Knoa Pharma Board Appoints Michael Goettler as President and Chief Executive Officer

Stamford, Conn., July 1, 2026 – Knoa Pharma today announced the appointment of Michael Goettler as President and Chief Executive Officer, effective July 6.